Opendata, web and dolomites

KILLCANCER SIGNED

Nanobody-targeted photodynamic therapy to kill cancer

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "KILLCANCER" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITEIT UTRECHT 

Organization address
address: HEIDELBERGLAAN 8
city: UTRECHT
postcode: 3584 CS
website: www.uu.nl

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Total cost 1˙500˙000 €
 EC max contribution 1˙500˙000 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2015-STG
 Funding Scheme ERC-STG
 Starting year 2016
 Duration (year-month-day) from 2016-07-01   to  2021-06-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITEIT UTRECHT NL (UTRECHT) coordinator 1˙500˙000.00

Map

 Project objective

Current cancer therapies often fail to cure patients. Ideally, therapy should locally eradicate cancer and should be capable of inducing long term protection, through activation of the immune system. Photodynamic therapy (PDT) is a treatment approach in which cancer cells are killed with compounds, named photosensitizers that are activated locally through light exposure. Importantly, PDT eradication of cancers commonly involves the immune system. However, current photosensitizers lack cancer specificity, which limits therapeutic efficacy and prolongs photosensitivity in patients. Recently, I have developed an improved version of targeted PDT that uses very small antibodies i.e. nanobodies that distribute homogenously, bind rapidly and specifically to cancer cells, and a photosensitizer that can be traced by optical imaging to guide the application of PDT. The aims of this proposal are to better understand and to advance nanobody-targeted PDT to ensure complete cancer eradication, and to facilitate its clinical translation. This will be achieved by: 1) Exploring the increased accumulation of photosensitizer through development of novel nanobody-photosensitizer conjugates to bind to cancer cells, cancer stem cells, and endothelial cells. These combinations will be evaluated for their efficacy in mice bearing human carcinomas; 2) Investigating the immune system activation to determine if, as other PDT, nanobody-targeted PDT triggers a systemic immune response, or if additional triggers are needed; 3) Studying the effect of nanobody-targeted PDT in dogs entering the veterinary clinic with oral or colorectal cancers. Treatment efficacy will be evaluated by monitoring cancer regression or disappearance. The outcome of this research will scientifically advance the new field of nanobody-targeted PDT, by providing essential information on its mechanism of action and the feasibility of this approach in human cancer patients, to ultimately improve current cancer treatment.

 Publications

year authors and title journal last update
List of publications.
2020 Beltrán Hernández, Yu, Ossendorp, Korbelik, Oliveira
Preclinical and Clinical Evidence of Immune Responses Triggered in Oncologic Photodynamic Therapy: Clinical Recommendations
published pages: 333, ISSN: 2077-0383, DOI: 10.3390/jcm9020333
Journal of Clinical Medicine 9/2 2020-02-13
2019 Else Driehuis, Sacha Spelier, Irati Beltrán Hernández, Remco de Bree, Stefan M. Willems, Hans Clevers, Sabrina Oliveira
Patient-Derived Head and Neck Cancer Organoids Recapitulate EGFR Expression Levels of Respective Tissues and Are Responsive to EGFR-Targeted Photodynamic Therapy
published pages: 1880, ISSN: 2077-0383, DOI: 10.3390/jcm8111880
Journal of Clinical Medicine 8/11 2020-01-30
2019 Timo W. M. De Groof, Vida Mashayekhi, Tian Shu Fan, Nick D. Bergkamp, Javier Sastre Toraño, Jeffrey R. van Senten, Raimond Heukers, Martine J. Smit, Sabrina Oliveira
Nanobody-Targeted Photodynamic Therapy Selectively Kills Viral GPCR-Expressing Glioblastoma Cells
published pages: 3145-3156, ISSN: 1543-8384, DOI: 10.1021/acs.molpharmaceut.9b00360
Molecular Pharmaceutics 16/7 2019-08-29
2019 Raimond Heukers, Vida Mashayekhi, Mercedes Ramirez-Escudero, Hans de Haard, Theo Verrips, Paul. van Bergen en Henegouwen, Sabrina Oliveira
VHH-Photosensitizer Conjugates for Targeted Photodynamic Therapy of Met-Overexpressing Tumor Cells
published pages: 26, ISSN: 2073-4468, DOI: 10.3390/antib8020026
Antibodies 8/2 2019-08-29
2017 Demian van Straten, Vida Mashayekhi, Henriette de Bruijn, Sabrina Oliveira, Dominic Robinson
Oncologic Photodynamic Therapy: Basic Principles, Current Clinical Status and Future Directions
published pages: 19, ISSN: 2072-6694, DOI: 10.3390/cancers9020019
Cancers 9/12 2019-06-19

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "KILLCANCER" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "KILLCANCER" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

Neuro-UTR (2019)

Mechanism and functional impact of ultra-long 3’ UTRs in the Drosophila nervous system

Read More  

AUTOMATION (2018)

AUTOMATION AND INCOME DISTRIBUTION: A QUANTITATIVE ASSESSMENT

Read More  

EllipticPDE (2019)

Regularity and singularities in elliptic PDE's: beyond monotonicity formulas

Read More